Imatinib for the adjuvant treatment of gastrointestinal stromal tumours - guidance (TA326)

National Institute for Health and Care Excellence - NICE
Publication date:
26 November 2014


Evidence-based recommendations on imatinib (Glivec) for treating gastrointestinal stromal tumours in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in April 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.